SEC Info - Sarepta Therapeutics, Inc.

SEC Info℠

Home

Help

Please Sign In

Sarepta Therapeutics, Inc. – ‘8-K’ for 5/18/21

On: Tuesday, 5/18/21, at 8:57am ET · For: 5/18/21 · Accession #: 1564590-21-28550 · File #: 1-14895

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/18/21  Sarepta Therapeutics, Inc.        8-K:7,9     5/18/21   12:5.6M                                   ActiveDisclosure/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     32K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     28K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     33K 
 8: R1          Document and Entity Information                     HTML     48K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- srpt-8k_20210518_htm                XML     15K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.LAB  XBRL Labels -- srpt-20210518_lab                     XML     58K 
 6: EX-101.PRE  XBRL Presentations -- srpt-20210518_pre              XML     36K 
 4: EX-101.SCH  XBRL Schema -- srpt-20210518                         XSD     19K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    20K 
12: ZIP         XBRL Zipped Folder -- 0001564590-21-028550-xbrl      Zip     22K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i 0000873303 0000873303 2021-05-18 2021-05-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i May 18, 2021

i Sarepta Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

i Delaware	i 001-14895	i 93-0797222
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i 215 First Street i Suite 415 i Cambridge, i MA i 02142
(Address of principal executive offices, including zip code)

Registrant’s Telephone Number, Including Area Code: ( i 617) i 274-4000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

i Common Stock, Par Value $0.0001 per share

i SRPT

i The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD Disclosure.

On May 18, 2021, Sarepta Therapeutics, Inc. (the “Company”) issued a press release and conducted an investor webcast presenting 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, the Company’s investigational gene therapy for the treatment of Duchenne muscular dystrophy. Copies of the press release and the presentation are being furnished as Exhibits 99.1 and 99.2, respectively.

The information in this report, furnished pursuant to Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated May 18, 2021: Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
99.2		Presentation dated May 18, 2021: Clinical Update: Micro-dystrophin Gene Therapy Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material
104		The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Sarepta Therapeutics, Inc.

Date: May 18, 2021	By:	/s/ *Douglas S. Ingram*
		Douglas S. Ingram
		President and Chief Executive Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	5/18/21	None on these Dates
		List all Filings

↑Top

Filing Submission 0001564590-21-028550 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)